My ePortfolio Register   

EMUC 2017: New data on prostate and urological cancers

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.11.17
Views: 620
Rating:

Prof Nicholas James, Prof Jeffrey Karnes and Prof Fred Witjes

Prof Nicholas James chairs a discussion with Prof Jeffrey Karnes and Prof Fred Witjes around the new data on treatment of prostate and other urological cancers presented at EMUC17.

They discuss findings from the APCC consensus session at EMUC17 with a focus on the debate around the number of nodes that should be removed in patients with high risk N0 M0 prostate cancer and whether this surgical procedure is undertaken for therapeutic or staging reasons.

Professor Karnes and Professor Witjes question Professor James on results from the STAMPEDE trial including details on the response of M0 patients and a comparison of patient response to docetaxel and abiraterone.

They discuss the future use of PARP inhibitors; how molecular testing will be done for these genetic mutations and the combination of these therapeutics with drugs including abiraterone.

The group then discuss immuno-therapy, sharing views on the need to identify biomarkers for treatment of patients with prostate cancer and how radiotherapy can have immunogenic effects on tumours resulting in better response to I-O therapies.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence